Medicare limits payments for new Alzheimer’s drug to clinical trials

Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.

View original article
Contributor: Lenny Bernstein